London, 15 October 2026: The Drug Design for Global Health (dd4gh) project, developed by deepmirror in partnership with Medicines for Malaria Venture (MMV), has been named on TIME’s Best Inventions of 2026 list in the Social Impact category.

Selected by TIME editors and correspondents worldwide, the annual list spotlights 300 groundbreaking inventions evaluated for originality, efficacy, ambition and impact. TIME’s recognition underscores the global importance of deepmirror’s mission: building the foundation model for drug design, built on the richest dataset of molecular properties.

Launched earlier this year, dd4gh is an open-access and free-to-use AI tool built to tackle the world’s most pressing global health challenges. dd4gh gives global health researchers access to advanced AI models for designing new molecules with the potential to shorten drug discovery timelines, reduce costs and open new avenues for discovering treatments for diseases that pose significant global health challenges.

Earlier in the summer, deepmirror and MMV also secured a $5 million grant for the continuation of their partnership on dd4gh. 

The proposed second generation of dd4gh will bring three-dimensional (3D) drug design into the platform, helping scientists to identify promising compounds sooner and deprioritise weaker ones. This phase will also incorporate capabilities to design long-acting injectable medicines, and predict the dose required to meet ideal product profiles. 

The dd4gh tool continues to be available free of charge to eligible researchers working on diseases that primarily affect populations in low- and middle-income countries, such as malaria, tuberculosis, antimicrobial resistance and neglected tropical diseases.

Researchers working on global health challenges can learn more about dd4gh and apply for access at dd4gh.ai

TIME’s Best Inventions of 2026 list is out now. See the full list here: https://ti.me/best-inventions

--

About MMV
‍MMV is a not-for-profit product development partnership working to discover, develop and deliver medicines to treat, prevent and eliminate malaria. Since 1999, over 1.48 billion people

have benefited from our co-developed medicines. With over 600,000 malaria deaths every year, we unite partners to close remaining antimalarial access and innovation gaps.  For more information, visit www.mmv.org.

About deepmirror
‍deepmirror is building the foundation model for drug design. AI for drug design is limited by sparse and fragmented data, but deepmirror's AI-native infrastructure empowers chemistry teams to better harness their data to progress programs faster, with fewer dead ends. With each project, deepmirror's data sets grow and the model improves, generating even greater outcomes. deepmirror is based in London and is already trusted by 100+ organisations across the globe. 

For more information, visit www.deepmirror.ai.

‍

For press enquiries, contact:‍

Hailey Eustace
deepmirror
+44 7480 559 199
hailey@commplicated.com

Doreen Akiyo Yomoah
Communications Manager, MMV
+41 79 238 60 74
yomoahd@mmv.org